Rosa A.
- Country
- Spain
- Department
- Servicio de hematologia
Research Overview
- Evaluation of INCA033989 Efficacy and Safety in Patients with Myelofibrosis or Essential Thrombocythemia within Myeloproliferative Neoplasms
- Evaluation of Selinexor Monotherapy Versus Physician's Choice in Patients with Previously Treated Myelofibrosis: A Phase 2, Randomized, Open-Label Study
- Phase 1b/2 Evaluation of BMS-986158 Alone and with Ruxolitinib or Fedratinib in DIPSS-Intermediate/High Risk Myelofibrosis Patients
Data & Insights
Has run more than one trial at 20 of 100 partner sites.
Specializations
Hematologic Disorders
The investigator specializes in the treatment of myelofibrosis, with particular focus on addressing intermediate and high-risk disease states.
- Advanced Myelofibrosis Management
- Risk-Stratified Treatment Approaches
- Progressive Disease Interventions
Expertise extends to evaluating novel therapeutic combinations for improving patient outcomes in myelofibrosis treatment.
Therapeutic Innovation
Primary interest lies in developing combination therapy strategies for hematologic conditions, particularly exploring novel treatment pathways for myelofibrosis.
- Novel Agent Development
- Combination Therapy Optimization
- Treatment Resistance Solutions
Focuses on advancing therapeutic options for patients who have experienced varied responses to existing treatments.
Clinical Assessment
Specializes in safety and tolerability evaluation of new therapeutic approaches for hematologic malignancies.
- Drug Safety Assessment
- Dose Optimization Studies
- Treatment Response Monitoring
Expertise in determining optimal dosing strategies and evaluating treatment efficacy in complex hematologic conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.